Zobrazeno 1 - 10
of 32
pro vyhledávání: ''
Autor:
Zhidan Zhang, Kaidi Song, Guangyu Sun, Baolin Tang, Meijuan Tu, Wen Yao, Xiaoyu Zhu, Tianzhong Pan, Liangquan Geng, Zimin Sun, Huilan Liu, Xiang Wan, Peng Ding, Yue Wu, Ping Qiang
Publikováno v:
Hematological Oncology. 40:83-92
Prolonged isolated thrombocytopenia (PIT) is a common complication after umbilical cord blood transplantation (UCBT). However, data on PIT prediction and impacts on transplantation outcomes for UCBT patients are rare. We retrospectively analyzed 244
Autor:
Qi Sun, Robert Peter Gale, Jinqin Liu, Bing Li, Zhijian Xiao, Shiqiang Qu, Huijun Huang, Zefeng Xu, Qingyan Gao, Meng Jiao, Wenyu Cai, Tiejun Qin, Junying Wu, Gang Huang, Lijuan Pan, Huijun Wang
Publikováno v:
Hematological Oncology. 39:728-732
In recent years, genome-based classifications for hematological neoplasms have been proposed successively and proved to be more accurate than histologic classifications. However, some previous studies have reported the racial differences of genetic l
Autor:
José Luis Díez-Martín, Elena Landete, Gillen Oarbeascoa, Nieves Dorado, Rebeca Bailén, Laura Solán, Mi Kwon, Javier Anguita
Publikováno v:
Hematological Oncology. 38:597-603
Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therap
Autor:
Lanfang Li, Wengui Xu, Xianhuo Wang, Huilai Zhang, Wenchao Ma, Zheng Song, Lihua Qiu, Shiyong Zhou, Peiqi Zhao, Lei Zhu, Zhengzi Qian, Xiang Zhu
Publikováno v:
Hematological Oncology. 38:493-500
The aim was to build a prognostic model to stratify patients at diagnosis into different risk categories. We investigated the prognostic value of functional PET parameters and clinical features in 64 primary breast lymphoma (PBL) patients. With a med
Autor:
Ronit Gurion, Uri Rozovski, Benaya Rozen-Zvi, Reem El-Saleh, Pia Raanani, Shai Shimony, Daniel Shepshelovich, Anat Gafter-Gvili, Irina Amitai
Publikováno v:
Hematological Oncology. 38:584-588
High dose methotrexate (HDMTX)-induced acute kidney injury (AKI) is a well-known adverse event in hemato-oncology patients. Our purpose was to define factors and setup cut-offs that may help better identify patients at-risk for developing AKI followi
Publikováno v:
Hematological Oncology. 38:334-343
This study aimed to evaluate the incidence and prognosis of primary cardiac lymphoma (PCL) by using the Surveillance, Epidemiology, and End Results Program (SEER) database. Patients diagnosed with PCL and the disease incidence in the SEER database fr
Autor:
Ahmed Sawas, Enrica Marchi, Govind Bhagat, Lorenzo Falchi, Owen A. O'Connor, Bin Cheng, Helen Ma
Publikováno v:
Hematological Oncology. 38:51-58
The peripheral T-cell lymphomas (PTCL) are rare and heterogeneous diseases characterized by an unfavorable prognosis. Chemotherapy is standard upfront treatment in most patients, but responses are short-lived with few FDA-approved "novel" agents avai
Publikováno v:
Hematological Oncology
Autor:
Koji, Kato, Naokuni, Uike, Atsushi, Wake, Makoto, Yoshimitsu, Tomomi, Tobai, Yasushi, Sawayama, Yoshifusa, Takatsuka, Takahiro, Fukuda, Naoyuki, Uchida, Tetsuya, Eto, Yasuhiro, Nakashima, Tadakazu, Kondo, Jun, Taguchi, Toshihiro, Miyamoto, Hirohisa, Nakamae, Tatsuo, Ichinohe, Ritsuro, Suzuki, Atae, Utsunomiya
Publikováno v:
Hematological Oncology. 37:54-61
Treatment options for patients with adult T cell leukemia/lymphoma (ATLL) who have relapsed disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. To clarify which patients with ATLL are likely to benefit from these
Autor:
Hiroaki Miyoshi, Yuya Sasaki, Masao Seto, Koichi Ohshima, Jun Takizawa, Takaharu Suzuki, Junichi Kiyasu, Keisuke Kawamoto, Hirohito Sone, Shintaro Yokoyama
Publikováno v:
Hematological Oncology. 36:591-599
Myeloid sarcoma (MS) is a rare condition and is an extramedullary tumour of immature myeloid cells. It is now known that the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway suppresses the host antitumor responses and that these pr